In vivo synthesis of cyclic-di-GMP using a recombinant adenovirus preferentially improves adaptive immune responses against extracellular antigens

Journal of Immunology

Volumn 196, Issue 4, 2016, Pages 1741-1752

  Alyaqoub, Fadel S ^a   Aldhamen, Yasser A ^a   Koestler, Benjamin J ^a,b   Bruger, Eric L ^a,b   Seregin, Sergey S ^a   Pereira Hicks, Cristiane ^a   Godbehere, Sarah ^a   Waters, Christopher M ^a,b   Amalfitano, Andrea ^a,c  

^a 4194 Biomedical and Physical Sciences Building ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CLOSTRIDIUM DIFFICILE TOXIN B; CYCLIC DIMERIC GUANOSINE MONOPHOSPHATE; CYCLIC GMP; GAG PROTEIN; INTERLEUKIN 2; OVALBUMIN; UNCLASSIFIED DRUG; ANTIGEN; BIS(3',5')-CYCLIC DIGUANYLIC ACID; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME SYNTHESIS; HUMAN ADENOVIRUS 5; HUMORAL IMMUNITY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ADENOVIRIDAE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE VECTOR; GENETIC TRANSDUCTION; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; WESTERN BLOTTING;

ADAPTIVE IMMUNITY; ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; BLOTTING, WESTERN; CYCLIC GMP; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENETIC VECTORS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSDUCTION, GENETIC;

EID: 84958582181     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501272     Document Type: Article

References (70)

1. Alving, C. R., K. K. Peachman, M. Rao, and S. G. Reed. 2012. Adjuvants for human vaccines. Curr. Opin. Immunol. 24: 310-315.
2. Vessely, C., T. Estey, T. W. Randolph, I. Henderson, J. Cooper, R. Nayar, L. J. Braun, and J. F. Carpenter. 2009. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J. Pharm. Sci. 98: 2970-2993.
3. Ahmed, S. S., S. A. Plotkin, S. Black, and R. L. Coffman. 2011. Assessing the safety of adjuvanted vaccines. Sci. Transl. Med. 3: 93rv2.
4. Gomelsky, M. 2012. Cyclic dimeric GMP-mediated decisions in surface-grown Vibrio parahaemolyticus: A different kind of motile-to-sessile transition. J. Bacteriol. 194: 911-913.
5. Krasteva, P. V., K. M. Giglio, and H. Sondermann. 2012. Sensing the messenger: The diverse ways that bacteria signal through c-di-GMP. Protein Sci. 21: 929-948.
6. Jones, J. W., N. Kayagaki, P. Broz, T. Henry, K. Newton, K. O'Rourke, S. Chan, J. Dong, Y. Qu, M. Roose-Girma, et al. 2010. Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc. Natl. Acad. Sci. USA 107: 9771-9776.
7. Parvatiyar, K., Z. Zhang, R. M. Teles, S. Ouyang, Y. Jiang, S. S. Iyer, S. A. Zaver, M. Schenk, S. Zeng, W. Zhong, et al. 2012. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat. Immunol. 13: 1155-1161.
8. Burdette, D. L., and R. E. Vance. 2013. STING and the innate immune response to nucleic acids in the cytosol. Nat. Immunol. 14: 19-26.
9. McWhirter, S. M., R. Barbalat, K. M. Monroe, M. F. Fontana, M. Hyodo, N. T. Joncker, K. J. Ishii, S. Akira, M. Colonna, Z. J. Chen, et al. 2009. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J. Exp. Med. 206: 1899-1911.
10. Karaolis, D. K., M. W. Newstead, X. Zeng, M. Hyodo, Y. Hayakawa, U. Bhan, H. Liang, and T. J. Standiford. 2007. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect. Immun. 75: 4942-4950.
11. Brouillette, E., M. Hyodo, Y. Hayakawa, D. K. Karaolis, and F. Malouin. 2005. 39,59-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection. Antimicrob. Agents Chemother. 49: 3109-3113.
12. Hu, D. L., K. Narita, M. Hyodo, Y. Hayakawa, A. Nakane, and D. K. Karaolis. 2009. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Vaccine 27: 4867-4873.
13. Elahi, S., J. Van Kessel, T. G. Kiros, S. Strom, Y. Hayakawa, M. Hyodo, L. A. Babiuk, and V. Gerdts. 2014. c-di-GMP enhances protective innate immunity in a murine model of pertussis. PLoS One 9: e109778.
14. Yan, H., R. KuoLee, K. Tram, H. Qiu, J. Zhang, G. B. Patel, and W. Chen. 2009. 39,59-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. Biochem. Biophys. Res. Commun. 387: 581-584.
15. Pedersen, G. K., T. Ebensen, I. H. Gjeraker, S. Svindland, G. Bredholt, C. A. Guzmán, and R. J. Cox. 2011. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One 6: e26973.
16. Svindland, S. C., G. K. Pedersen, R. D. Pathirana, G. Bredholt, J. K. Nøstbakken, A . Jul-Larsen, C. A. Guzmán, E. Montomoli, G. Lapini, S. Piccirella, et al. 2013. A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respi. Viruses 7: 1181-1193.
17. Huang, L., L. Li, H. Lemos, P. R. Chandler, G. Pacholczyk, B. Baban, G. N. Barber, Y. Hayakawa, T. L. McGaha, B. Ravishankar, et al. 2013. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J. Immunol. 191: 3509-3513.
18. Lemos, H., L. Huang, P. R. Chandler, E. Mohamed, G. R. Souza, L. Li, G. Pacholczyk, G. N. Barber, Y. Hayakawa, D. H. Munn, and A. L. Mellor. 2014. Activation of the STING adaptor attenuates experimental autoimmune encephalitis. J. Immunol. 192: 5571-5578.
19. Karaolis, D. K., T. K. Means, D. Yang, M. Takahashi, T. Yoshimura, E. Muraille, D. Philpott, J. T. Schroeder, M. Hyodo, Y. Hayakawa, et al. 2007. Bacterial c-di-GMP is an immunostimulatory molecule. J. Immunol. 178: 2171-2181.
20. Fatima, M., H. Rempel, X. T. Kuang, K. J. Allen, K. M. Cheng, F. Malouin, and M. S. Diarra. 2013. Effect of 39,59-cyclic diguanylic acid in a broiler Clostridium perfringens infection model. Poult. Sci. 92: 2644-2650.
21. Miyabe, H., M. Hyodo, T. Nakamura, Y. Sato, Y. Hayakawa, and H. Harashima. 2014. A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy. J. Control. Release 184: 20-27.
22. Chandra, D., W. Quispe-Tintaya, A. Jahangir, D. Asafu-Adjei, I. Ramos, H. O. Sintim, J. Zhou, Y. Hayakawa, D. K. Karaolis, and C. Gravekamp. 2014. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol. Res. 2: 901-910.
23. Ohkuri, T., A. Ghosh, A. Kosaka, J. Zhu, M. Ikeura, M. David, S. C. Watkins, S. N. Sarkar, and H. Okada. 2014. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol. Res. 2: 1199-1208.
24. Beyhan, S., L. S. Odell, and F. H. Yildiz. 2008. Identification and characterization of cyclic diguanylate signaling systems controlling rugosity in Vibrio cholerae. J. Bacteriol. 190: 7392-7405.
25. Lim, B., S. Beyhan, J. Meir, and F. H. Yildiz. 2006. Cyclic-diGMP signal transduction systems in Vibrio cholerae: modulation of rugosity and biofilm formation. Mol. Microbiol. 60: 331-348.
26. Beyhan, S., and F. H. Yildiz. 2007. Smooth to rugose phase variation in Vibrio cholerae can be mediated by a single nucleotide change that targets c-di-GMP signalling pathway. Mol. Microbiol. 63: 995-1007.
27. Shikuma, N. J., J. C. Fong, and F. H. Yildiz. 2012. Cellular levels and binding of c-di-GMP control subcellular localization and activity of the Vibrio cholerae transcriptional regulator VpsT. PLoS Pathog. 8: e1002719.
28. Galperin, M. Y. 2004. Bacterial signal transduction network in a genomic perspective. Environ. Microbiol. 6: 552-567.
29. Hunter, J. L., G. B. Severin, B. J. Koestler, and C. M. Waters. 2014. The Vibrio cholerae diguanylate cyclase VCA0965 has an AGDEF active site and synthesizes cyclic di-GMP. BMC Microbiol. 14: 22.
30. Koestler, B. J., S. S. Seregin, D. P. Rastall, Y. A. Aldhamen, S. Godbehere, A. Amalfitano, and C. M. Waters. 2014. Stimulation of innate immunity by in vivo cyclic di-GMP synthesis using adenovirus. Clin. Vaccine Immunol. 21: 1550-1559.
31. Aldhamen, Y. A., D. M. Appledorn, S. S. Seregin, C. J. Liu, N. J. Schuldt, S. Godbehere, and A. Amalfitano. 2011. Expression of the SLAM family of receptors adapter EAT-2 as a novel strategy for enhancing beneficial immune responses to vaccine antigens. J. Immunol. 186: 722-732.
32. Seregin, S. S., Y. A. Aldhamen, D. M. Appledorn, Z. C. Hartman, N. J. Schuldt, J. Scott, S. Godbehere, H. Jiang, M. M. Frank, and A. Amalfitano. 2010. Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood 116: 1669-1677.
33. Appledorn, D.M., Y. A. Aldhamen,W. Depas, S. S. Seregin, C. J. Liu, N. Schuldt, D. Quach, D. Quiroga, S. Godbehere, I. Zlatkin, et al. 2010. A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. PLoS One 5: e9579.
34. Seregin, S. S., Y. A. Aldhamen, D. P. Rastall, S. Godbehere, and A. Amalfitano. 2012. Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine 30: 1492-1501.
35. Barroso, L. A., S. Z. Wang, C. J. Phelps, J. L. Johnson, and T. D. Wilkins. 1990. Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res. 18: 4004.
36. Kink, J. A., and J. A. Williams. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 66: 2018-2025.
37. Aldhamen, Y. A., S. S. Seregin, N. J. Schuldt, D. P. Rastall, C. J. Liu, S. Godbehere, and A. Amalfitano. 2012. Vaccines expressing the innate immune modulator EAT-2 elicit potent effector memory T lymphocyte responses despite pre-existing vaccine immunity. J. Immunol. 189: 1349-1359.
38. Seregin, S. S., D. M. Appledorn, A. J. McBride, N. J. Schuldt, Y. A. Aldhamen, T. Voss, J. Wei, M. Bujold, W. Nance, S. Godbehere, and A. Amalfitano. 2009. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol. Ther. 17: 685-696.
39. Massie, J. P., E. L. Reynolds, B. J. Koestler, J. P. Cong, M. Agostoni, and C. M. Waters. 2012. Quantification of high-specificity cyclic diguanylate signaling. Proc. Natl. Acad. Sci. USA 109: 12746-12751.
40. Appledorn, D. M., Y. A. Aldhamen, S. Godbehere, S. S. Seregin, and A. Amalfitano. 2011. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity. Clin. Vaccine Immunol. 18: 150-160.
41. Ahlén, G., L. Strindelius, T. Johansson, A. Nilsson, N. Chatzissavidou, M. Sjöblom, U. Rova, and J. Holgersson. 2012. Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses. PLoS One 7: e46959.
42. Basto, A. P., M. Badenes, S. C. Almeida, C. Martins, A. Duarte, D. M. Santos, and A. Leitaõ. 2015. Immune response profile elicited by the model antigen ovalbumin expressed in fusion with the bacterial OprI lipoprotein. Mol. Immunol. 64: 36-45.
43. Garulli, B., M. G. Stillitano, V. Barnaba, and M. R. Castrucci. 2008. Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. Clin. Vaccine Immunol. 15: 1497-1504.
44. Gabitzsch, E. S., Y. Xu, L. H. Yoshida, J. Balint, R. B. Gayle, A. Amalfitano, and F. R. Jones. 2009. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunol. Lett. 122: 44-51.
45. Schuldt, N. J., Y. A. Aldhamen, D. M. Appledorn, S. S. Seregin, Y. Kousa, S. Godbehere, and A. Amalfitano. 2011. Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses. PLoS One 6: e24147.
46. Rueckert, C., and C. A. Guzmán. 2012. Vaccines: from empirical development to rational design. PLoS Pathog. 8: e1003001.
47. Hornung, V., A. Ablasser, M. Charrel-Dennis, F. Bauernfeind, G. Horvath, D. R. Caffrey, E. Latz, and K. A. Fitzgerald. 2009. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458: 514-518.
48. Fernandes-Alnemri, T., J. W. Yu, P. Datta, J. Wu, and E. S. Alnemri. 2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458: 509-513.
49. Blaauboer, S. M., V. D. Gabrielle, and L. Jin. 2014. MPYS/STING-mediated TNF-a, not type I IFN, is essential for the mucosal adjuvant activity of (39-59)-cyclic-di-guanosine-monophosphate in vivo. J. Immunol. 192: 492-502.
50. Blaauboer, S. M., S. Mansouri, H. R. Tucker, H. L. Wang, V. D. Gabrielle, and L. Jin. 2015. The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo. eLife 4: 4.
51. Wu, J., L. Sun, X. Chen, F. Du, H. Shi, C. Chen, and Z. J. Chen. 2013. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339: 826-830.
52. Ablasser, A., J. L. Schmid-Burgk, I. Hemmerling, G. L. Horvath, T. Schmidt, E. Latz, and V. Hornung. 2013. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 503: 530-534.
53. Zhang, X., H. Shi, J. Wu, X. Zhang, L. Sun, C. Chen, and Z. J. Chen. 2013. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 51: 226-235.
54. Li, X. D., J. Wu, D. Gao, H. Wang, L. Sun, and Z. J. Chen. 2013. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341: 1390-1394.
55. Gao, D., J. Wu, Y. T. Wu, F. Du, C. Aroh, N. Yan, L. Sun, and Z. J. Chen. 2013. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341: 903-906.
56. Skrnjug, I., C. A. Guzmán, and C. Rueckert. 2014. Cyclic GMP-AMP displays mucosal adjuvant activity in mice. [Published erratum appears in 2015 PLoS One 10: e0123605.] PLoS One 9: e110150.
57. Tibbles, L. A., J. C. Spurrell, G. P. Bowen, Q. Liu, M. Lam, A. K. Zaiss, S. M. Robbins, M. D. Hollenberg, T. J. Wickham, and D. A. Muruve. 2002. Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J. Virol. 76: 1559-1568.
58. Verdino, P., D. A. Witherden, W. L. Havran, and I. A. Wilson. 2010. The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K. Science 329: 1210-1214.
59. Appledorn, D. M., S. Patial, A. McBride, S. Godbehere, N. Van Rooijen, N. Parameswaran, and A. Amalfitano. 2008. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 181: 2134-2144.
60. Zhu, J., X. Huang, and Y. Yang. 2007. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J. Virol. 81: 3170-3180.
61. Appledorn, D. M., S. Patial, S. Godbehere, N. Parameswaran, and A. Amalfitano. 2009. TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses. J. Innate Immun. 1: 376-388.
62. Ishii, K. J., T. Kawagoe, S. Koyama, K. Matsui, H. Kumar, T. Kawai, S. Uematsu, O. Takeuchi, F. Takeshita, C. Coban, and S. Akira. 2008. TANKbinding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451: 725-729.
63. Quinn, K. M., D. E. Zak, A. Costa, A. Yamamoto, K. Kastenmuller, B. J. Hill, G. M. Lynn, P. A. Darrah, R. W. Lindsay, L. Wang, et al. 2015. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J. Clin. Invest. 125: 1129-1146.
64. Soumelis, V., and Y. J. Liu. 2006. From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur. J. Immunol. 36: 2286-2292.
65. Renneson, J., M. Salio, N. Mazouz, M. Goldman, A. Marchant, and V. Cerundolo. 2005. Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8 T cells. Clin. Exp. Immunol. 139: 468-475.
66. Huber, J. P., and J. D. Farrar. 2011. Regulation of effector and memory T-cell functions by type I interferon. Immunology 132: 466-474.
67. Gray, P. M., G. Forrest, T. Wisniewski, G. Porter, D. C. Freed, J. A. DeMartino, D. M. Zaller, Z. Guo, J. Leone, T. M. Fu, and K. A. Vora. 2012. Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell. Immunol. 278: 113-119.
68. Karaolis, D. K., K. Cheng, M. Lipsky, A. Elnabawi, J. Catalano, M. Hyodo, Y. Hayakawa, and J. P. Raufman. 2005. 39,59-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem. Biophys. Res. Commun. 329: 40-45.
69. Joshi, V. B., S. M. Geary, B. P. Gross, A. Wongrakpanich, L. A. Norian, and A. K. Salem. 2014. Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev. Vaccines 13: 9-15.
70. Archer, K. A., J. Durack, and D. A. Portnoy. 2014. STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog. 10: e1003861.